Status:
COMPLETED
Ciclesonide for the Treatment of Airway Hyperresponsiveness
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The study objective is to investigate in a placebo-controlled, double-blind manner the effect of inhaled corticosteroid (ciclesonide) on airway hyperresponsiveness measured as having PD15 mannitol. Tr...
Eligibility Criteria
Inclusion
- Referred to the pulmonology department of the university hospital Basel because of suspected asthma defined as respiratory symptoms like wheezing or cough or chest tightness.
- Asthma symptoms partly controlled according to GINA (October 2006) 1 week prior to randomization
- FEV1 ≥ 70% predicted
- 18 - 70 years old
Exclusion
- Smoker and ex-smoker with \>10 pack years
- COPD
- Upper respiratory tract infection within the past 4 weeks.
- ICS or oral steroids during the previous month before inclusion
- b-blockers within the past 4 weeks
- Current treatment with medication as defined in section concomitant medication (ICS other than study medication, ß-blockers)
- Pregnancy
- Known malignancy
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00826969
Start Date
September 1 2008
End Date
October 1 2011
Last Update
December 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed
Basel, Switzerland, 4031